Professor Aurélien Marabelle joins the Board of Directors of the Society for Immunotherapy of Cancer (SITC)
Professor Aurélien Marabelle, physician-scientist at Gustave Roussy, has been elected to a three-year term on the Board of Directors of the SITC, the leading international scientific society dedicated to cancer immunotherapy. His term will begin in January 2026, during the annual renewal of one-third of the board members.
Founded in 1985, the SITC is celebrating its 40th anniversary and brings together more than 2,400 experts from 42 countries. This election highlights Professor Marabelle’s pioneering role and Gustave Roussy’s commitment to therapeutic innovation. He will be the first and only French and European representative on the SITC Board.
Trained at the École Normale Supérieure de Lyon, King’s College London, and Stanford University, Professor Marabelle works at the intersection of clinical and translational research. He is an oncologist in the Department of Therapeutic Innovation and Early Trials (DITEP), Professor of Clinical Immunology at Université Paris-Saclay, and leads the INSERM Translational Research Laboratory in Immunotherapy (LRTI) at Gustave Roussy. He also coordinates the RHU (Hospital-University Research) program REMISSION, a project supported by the France 2030 plan to accelerate access to immunotherapy.
A specialist in next-generation immunotherapies, he is the author of more than 250 scientific publications and leads numerous early-phase clinical trials. He co-founded the French Society for Cancer Immunotherapy (FITC), where he currently serves as Vice-President, and sits on several international scientific committees.
“It is an honor to join the SITC Board of Directors at a strategic moment of exponential growth in immunotherapy approaches. This election commits me to promoting an ambitious scientific vision based on European academic excellence, while also fostering international collaboration, broad dissemination of knowledge, and equitable access to innovation,” he stated.